Evotec achieves important milestone
TargetAD collaboration with Janssen in Alzheimer's disease
Evotec AG announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the transition of a project into further drug discovery process. This milestone was reached in 2015 which will be recognised in the financial year 2015.
The agreement between Evotec and Janssen for this collaboration became effective on October 31, 2013. Johnson & Johnson Innovation, LLC facilitates the collaboration. Under the terms of the agreement, Janssen and Evotec continue to collaborate to develop new drugs for Alzheimer's disease. Janssen has the right to internalise selected targets and therapeutic candidates and progress them into pre-clinical and clinical development. Janssen funds target drug discovery research via a combination of defined research payments and progress-related milestones.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Despite the significant challenges in identifying and prosecuting novel targets in the field of Alzheimer's disease, our collaboration with Janssen continues to thrive as documented by this milestone. On the basis of an ever improving platform and an excellent team that is seamlessly integrated across both companies, we are confident that further progress will follow in 2016."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
